Tagged with biosimilars,

Italy EG STADA’s General Manager & Managing Director Italy, Salvatore Butti, explains the company’s strong heritage in generics, the solid presence it is developing in consumer healthcare with new acquisitions from GSK and Sanofi, and its biosimilar and specialties market inroads.  In addition, he tells us about the STADA Health Report,…

Spain Its unorthodox name reflecting a somewhat unconventional approach, mAbxience has achieved some significant milestones in its short history, including becoming the only privately-owned company in the world with less than 500 people to have launched a monoclonal antibody biosimilar. “This is not usually a small company game, and mAbxience did…

Italy Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic products. Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business…

Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe.    Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…

Europe The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his perspective on recent policy changes at a national and continental level. With over ten years of experience with the company,…

Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…

Korea Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP certification from the US FDA in 2007 and another one to launch an initial public offering; an ascent that, while…

Spain Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to transforming neuroscience. The Portuguese executive also analyzes what he describes as a “positive” momentum for biosimilars in Spain amongst his…

Global With Biogen’s recent move to sell off its USD 2.3 billion stake in biosimilars firm Samsung Bioepis against the backdrop of lower-than-expected uptake of its controversial Alzheimer’s Disease drug Aduhelm, PharmaBoardroom takes a look at the contrasting fortunes of two key firms operating in the global biosimilars market today.   Global…

Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…

Spain mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing facility, and its partnership with AstraZeneca on COVID-19 vaccine manufacturing in Argentina. As representatives from the US FDA carried out a Good Clinical Practice inspection in an adjacent office, Lepine outlined…

Global In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status of the biosimilars industry, the differences between the European and US markets, the advantages of being part of a large science-based innovator like Novartis, and why competition in biosimilars will…